Asahi Kasei says Japan approves Empaveli for C3 glomerulopathy, immune complex MPGN

PUBT · 1d ago
Asahi Kasei says Japan approves Empaveli for C3 glomerulopathy, immune complex MPGN
  • Japan cleared Empaveli for C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, expanding Asahi Kasei’s rare-kidney portfolio.
  • Sobi Japan will supply the drug as marketing authorization holder; Asahi Kasei Therapeutics will distribute it.
  • Label covers patients aged 12 and older; positioned as Japan’s first complement inhibitor for these indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.